CardioFocus wraps $20M financing round to support endoscopic ablation system

Medical device maker CardioFocus (Marlborough, MA), which is dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF), has completed a $20 million round in equity financing. The proceeds will be used to support the company's expanding commercialization of its HeartLight endoscopic ablation system, a catheter laser ablation technology designed for the treatment of AF. The device received CE Mark approval in 2009 and FDA clearance in April 2016.

The financing will also further the company's technology development programs, including the ongoing clinical evaluation of its next-generation HeartLight Excalibur Balloon, which introduces an advanced feature set that optimizes the speed and magnitude of target tissue contact during pulmonary vein isolation (PVI) procedures.

The HeartLight endoscopic ablation system offers direct visualization, titratable laser energy, and a universal balloon design for PVI procedures. Commercially available in the U.S. and Europe, more than 4000 patients with AF have been successfully treated with the system.

In the U.S., the HeartLight System is also indicated for the treatment of drug refractory recurrent symptomatic paroxysmal AF.

For more information, please visit www.cardiofocus.com.